Alpine Immune Sciences (NASDAQ:ALPN) Stock Rating Reaffirmed by HC Wainwright

Alpine Immune Sciences (NASDAQ:ALPN)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $17.00 target price on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 43.34% from the stock’s previous close.

A number of other equities research analysts have also issued reports on ALPN. Oppenheimer upped their target price on shares of Alpine Immune Sciences from $14.00 to $22.00 and gave the company an “outperform” rating in a research note on Monday. Wedbush reiterated an “outperform” rating and issued a $19.00 price objective on shares of Alpine Immune Sciences in a report on Friday, September 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $18.00.

Alpine Immune Sciences Trading Up 0.5 %

Shares of Alpine Immune Sciences stock opened at $11.86 on Wednesday. The company has a fifty day moving average price of $12.53 and a 200 day moving average price of $10.08. The stock has a market cap of $583.54 million, a price-to-earnings ratio of -8.59 and a beta of 1.27. Alpine Immune Sciences has a twelve month low of $4.82 and a twelve month high of $14.92.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.11. The company had revenue of $8.59 million during the quarter, compared to analysts’ expectations of $8.08 million. Alpine Immune Sciences had a negative net margin of 201.07% and a negative return on equity of 33.44%. Analysts forecast that Alpine Immune Sciences will post -1.29 earnings per share for the current year.

Institutional Investors Weigh In On Alpine Immune Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its stake in Alpine Immune Sciences by 99.1% in the 2nd quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 1,315 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in Alpine Immune Sciences in the 3rd quarter valued at $35,000. Barclays PLC grew its position in Alpine Immune Sciences by 818.4% in the 4th quarter. Barclays PLC now owns 6,080 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 5,418 shares during the last quarter. BNP Paribas Arbitrage SNC grew its position in Alpine Immune Sciences by 88.7% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 3,090 shares during the last quarter. Finally, American International Group Inc. grew its position in Alpine Immune Sciences by 26.8% in the 2nd quarter. American International Group Inc. now owns 7,310 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 1,543 shares during the last quarter. Hedge funds and other institutional investors own 75.17% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc, a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy.